Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS. Kulke MH, et al. Among authors: blaszkowsky ls. Cancer Chemother Pharmacol. 2011 Aug;68(2):293-300. doi: 10.1007/s00280-010-1478-7. Epub 2010 Oct 20. Cancer Chemother Pharmacol. 2011. PMID: 20960192 Free PMC article. Clinical Trial.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Willett CG, et al. Among authors: blaszkowsky ls. Nat Med. 2004 Feb;10(2):145-7. doi: 10.1038/nm988. Epub 2004 Jan 25. Nat Med. 2004. PMID: 14745444 Free PMC article. Clinical Trial.
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Willett CG, et al. Among authors: blaszkowsky ls. J Clin Oncol. 2005 Nov 1;23(31):8136-9. doi: 10.1200/JCO.2005.02.5635. J Clin Oncol. 2005. PMID: 16258121 Clinical Trial. No abstract available.
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Zhu AX, et al. Among authors: blaszkowsky ls. Cancer. 2007 Aug 1;110(3):581-9. doi: 10.1002/cncr.22829. Cancer. 2007. PMID: 17583545 Free article. Clinical Trial.
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, Christiani DC, Liu G. Asomaning K, et al. Clin Cancer Res. 2008 Jun 15;14(12):4010-5. doi: 10.1158/1078-0432.CCR-07-4187. Clin Cancer Res. 2008. PMID: 18559624
137 results